Neogenomics
NeoGenomics Laboratories, a leading provider of cancer-focused genetic testing services, is headquartered in the United States. Founded in 2001, the company has established itself as a key player in the oncology diagnostics industry, with major operational regions across North America and Europe. NeoGenomics offers a comprehensive range of services, including molecular testing, pathology, and clinical trial support, distinguished by their commitment to innovation and accuracy. Their advanced testing capabilities, such as next-generation sequencing and liquid biopsy, set them apart in a competitive market. With a strong market position, NeoGenomics has achieved notable milestones, including partnerships with prominent healthcare institutions and a growing portfolio of proprietary tests. Their dedication to improving patient outcomes through precision medicine continues to drive their success in the evolving landscape of cancer diagnostics.
DitchCarbon Score
How does Neogenomics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neogenomics's score of 23 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Neogenomics's reported carbon emissions
In 2023, Neogenomics reported total carbon emissions of approximately 4,717,000 kg CO2e, comprising 536,000 kg CO2e from Scope 1 emissions and 4,181,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Despite the significant total emissions, there are currently no specific reduction targets or initiatives outlined in their climate commitments. Neogenomics has not made any pledges towards science-based targets or other formal climate commitments, indicating a potential area for future development in their sustainability strategy. As a leading entity in the healthcare sector, Neogenomics' emissions profile reflects the industry's broader challenges in addressing climate change, highlighting the importance of establishing clear reduction goals and strategies moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 536,000 |
| Scope 2 | 4,181,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neogenomics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
